Mucositis News and Research

RSS
Trial of treatment of inflammatory bowel disease begins at Tel Aviv Sourasky Medical Center

Trial of treatment of inflammatory bowel disease begins at Tel Aviv Sourasky Medical Center

Report says cancer clinicians should understand and consider the economic impact of new interventions

Report says cancer clinicians should understand and consider the economic impact of new interventions

Canopus BioPharma enters phase II clinical trials with CB1400

Canopus BioPharma enters phase II clinical trials with CB1400

Results of phase II studies of pazopanib

Results of phase II studies of pazopanib

CuraGen announces results with Belinostat and Velafermin

CuraGen announces results with Belinostat and Velafermin

Access Pharmaceuticals receives MuGard patent allowance

Access Pharmaceuticals receives MuGard patent allowance

Cetuximab with radiotherapy does not increase side effects for head and neck cancer patients

Cetuximab with radiotherapy does not increase side effects for head and neck cancer patients

First drug treatment for late-stage cervical cancer approved

First drug treatment for late-stage cervical cancer approved

Tetracaine mouthwash helps with pain linked to head and neck cancer

Tetracaine mouthwash helps with pain linked to head and neck cancer

Intensity modulated radiation therapy (IMRT) for head and neck cancer

Intensity modulated radiation therapy (IMRT) for head and neck cancer

Preclinical data suggest CuraGen's Velafermin may protect the gastrointestinal tract and decrease associated toxicity following exposure to radiation

Preclinical data suggest CuraGen's Velafermin may protect the gastrointestinal tract and decrease associated toxicity following exposure to radiation

Simple analysis of a bone marrow transplant patient's oral rinse indicates whether infection will develop

Simple analysis of a bone marrow transplant patient's oral rinse indicates whether infection will develop

Single dose phase I data on CG53135 for the prevention of oral mucositis

Single dose phase I data on CG53135 for the prevention of oral mucositis

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

MGI PHARMA acquires Aesgen for $32 million

MGI PHARMA acquires Aesgen for $32 million